PURPOSECannabis has been legalized across multiple states over the past decade; however, its use among cancer survivors ...

At disease-free survival (DFS) interim analysis (clinical cutoff: January 21, 2021; median follow-up, 32.2 months), the IMpower010 study met its primary end point, with statistically significant DFS ...

This retrospective analysis included patients with cancer who had commercial ctDNA tests (K-Track, Gene Solutions, Vietnam) between August 2022 and December 2023. A personalized tumor-informed ctDNA ...

Although the incidence of breast cancer is higher in LMICs, patients are delaying seeking medical attention. A study report showed that patient presentation with breast cancer in LMICs has ...

Background: Advances in cancer diagnostics including genomic testing has improved our ability to determine the likely tissue of origin (TOO) in CUP. We aimed to describe the clinical and molecular ...

Study population consisted of 10,717 individuals, with a median age of 65 years and a majority of de novo mHSPC cases at diagnosis (62%). Overall, 28% received combination therapy with ARPI (18% ...

Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies, which is often limited by ...

Not surprisingly, women receiving the CDK4/6 inhibitors in the adjuvant setting had an increased probability of nausea, hair thinning, hepatic function abnormalities, fatigue, infection risk, and ...

Although there is a growing number of people living with advanced or metastatic cancer, primarily because of more effective treatment regimens, there are limited estimates of the actual number of ...

Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial ...

Homologous recombination deficiency (HRD) assays measure DNA damage repair dysfunction to identify patients with high-grade serous ovarian cancer (HGSOC) who may benefit from poly ADP-ribose ...

We identified clinically relevant PGx variants across the four genes in 62.7% of participants in our cohort. Extending this to annual prescription numbers in England for the drugs affected by these ...